Metsera, Inc.
MTSR
Rang in Aktien
#2573
Metsera, Inc. operates as a clinical-stage biotechnology firm, specializing in... Metsera, Inc. operates as a clinical-stage biotechnology firm, specializing in crafting both injectable and oral nutrient-stimulated hormone analog peptides. These therapeutic compounds are primarily aimed at addressing obesity, overweight conditions, and associated health issues. Its developmental pipeline features MET-097i and MET-233i, both under investigation for treating obesity and overweight patients. Furthermore, Metsera is advancing a potential combination therapy involving MET-233i and MET-097i. The company is also progressing additional drug candidates, including MET-002, MET-224o, MET-067i, and MET-034i, all of which target disorders such as diabetes and obesity. Founded in 2022, Metsera, Inc. maintains its corporate headquarters in New York, New York.
Aktienkurs
$70.50
Zuletzt synchronisiert: 2025-11-14
Marktkapitalisierung
$7.33B
Veränderung (1 Tag)
0.00%
Veränderung (1 Jahr)
33.60%
Land
US
Handel Metsera, Inc. (MTSR)
Kategorie
Healthcare
Dividendenrendite-Verlauf für Metsera, Inc. (MTSR)
Dividendenrendite (TTM) von Metsera, Inc. (Aktienkürzel: MTSR) zum 2026: 0
Durchschnittliche Dividendenrendite der letzten 5 Jahre: 0.00%
Durchschnittliche Dividendenrendite der letzten 5 Jahre: 0.00%
Dividendenrendite-Verlauf für Metsera, Inc. (MTSR) von 2023 bis 2026
Dividendenrendite am Ende jedes Jahres (TTM)
| Jahr | Dividendenrendite | ändert |
|---|---|---|
| 2024 | 0.00% | 0.00% |
| 2023 | 0.00% | 0.00% |
Dividendenrenditen (TTM) für ähnliche Unternehmen oder Wettbewerber
| Unternehmen | Dividendenrendite | Land |
|---|---|---|
| 0.00% |
US
|
|
| 0.00% |
US
|
|
| 2.17% |
AU
|
|
| 0.00% |
NL
|
|
| 0.00% |
CH
|
